I

InfuSystem Holdings Inc
AMEX:INFU

Watchlist Manager
InfuSystem Holdings Inc
AMEX:INFU
Watchlist
Price: 8.89 USD -0.78% Market Closed
Market Cap: 180.8m USD

InfuSystem Holdings Inc
Investor Relations

InfuSystem Holdings, Inc. engages in the provision of healthcare services. The company is headquartered in Rochester Hills, Michigan and currently employs 420 full-time employees. The company went IPO on 2006-06-15. The Company’s segments include Integrated Therapy Services (ITS) and Durable Medical Equipment Services (DME Services). The Company’s core service within its ITS segment is its Oncology Business. The ITS segment supplies electronic ambulatory infusion pumps and associated disposable supply kits to private oncology clinics, infusion clinics and hospital outpatient oncology clinics to be utilized in the treatment of a variety of cancers, including colorectal cancer and other disease states. Its DME Services segments core service is to sell or rent new and pre-owned pole-mounted and ambulatory infusion pumps and other Durable Medical Equipment; sell treatment-related consumables; and provide biomedical recertification, maintenance and repair services for oncology practices as well as other healthcare site settings.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 4, 2025
AI Summary
Q3 2025

Record Revenue: InfuSystem reported record third quarter 2025 revenue of $36.5 million, up 3.3% from the prior year.

Margin Expansion: Gross margin reached just over 57%, up 3.1 percentage points year-over-year, with gross profit also a quarterly record.

Profitable Growth: Adjusted EBITDA rose 5.6% to $8.3 million, representing 22.8% of net revenue, even with significant ERP investment.

Wound Care & Oncology Strength: Wound Care revenue more than doubled, and Oncology revenue hit an all-time record, benefiting from new contracts and increased patient volumes.

Biomedical Contract Change: Major biomedical services contract restructured, reducing revenue by $6–7 million annually starting December, but expected to increase operating profit due to lower costs.

Cash Flow & Capital Return: Year-to-date operating cash flow exceeded $17 million, with $8.6 million returned to shareholders via buybacks and net debt reduced by $5.7 million in Q3.

Guidance Reaffirmed: Full-year 2025 outlook reaffirmed: revenue growth of 6–8% and adjusted EBITDA margin of at least 20%.

Key Financials
Revenue
$36.5 million
Wound Care Revenue
$2 million
Gross Profit
$20.8 million
Gross Margin
just over 57%
Adjusted EBITDA
$8.3 million
Adjusted EBITDA (TTM)
$30.2 million
Adjusted EBITDA Margin
22.8% (Q3), 21.4% (TTM)
Operating Cash Flow (YTD)
over $17 million
Net Capital Expenditures
$3.1 million (YTD)
Shareholder Capital Return (YTD)
$8.6 million
Available Liquidity
nearly $65 million as of September 30, 2025
Net Debt to Adjusted EBITDA
0.66x
ERP Project Expenses (Q3)
$770,000
Stock Repurchases (Q3)
$2.2 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Richard A. DiIorio
CEO & Director
No Bio Available
Ms. Carrie A. Lachance B.S.N., M.B.A., R.N.
President, COO & Director
No Bio Available
Mr. Barry G. Steele CPA
Executive VP & CFO
No Bio Available
Mr. Addam Chupa
Executive VP & Chief Information Officer
No Bio Available
Mr. Jerod Funke
Executive VP & Chief HR Officer
No Bio Available
Ms. Jeanie Latz
Corporate Secretary
No Bio Available

Contacts

Address
MICHIGAN
Rochester Hills
3851 West Hamlin Road
Contacts
+12482911210
ir.infusystem.com